25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical Review reported that Celltrion has finalised an agreement with Johnson...
BioBlast w/e 25 Aug 23
read more
BioBlast w/e 18 Aug 23
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the FDA approved its 8mg Eylea® (aflibercept) to treat Wet...
BioBlast w/e 12 Aug 23
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to the Business Standard Biocon Biologics’ CEO has confirmed the...
Car Park App Scrap Reaches the Merits Stage
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP dominates 2023 WIPR Leaders lists for Patents and Trade Marks
We are pleased to announce that 3 Pearce IP leaders are ranked amongst the world’s best patent and trade mark practitioners by WIPR Leaders 2023. Pearce IP’s Executives Naomi...
BioBlast w/e 04 Aug 23
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that it will still pursue launching its Alvotech...
BioBlast w/e 28 Jul 23
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...
‘Repair’ defence to patent infringement and the perils of hindsight bias
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 21 Jul 23
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Naomi Pearce is the 2023 Lawyers Weekly IP Partner of the Year
We are excited to announce that Naomi Pearce, (CEO, Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, was crowned the 2023 Intellectual Property...
Make priority your priority – ToolGen loses priority battle for CRISPR patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 14 Jul 23
14 JUL 2023 | EU | EMA confirms acceptance of Intas’ MAA for its ustekinemab (Stelara®) biosimilar Intas Pharmaceuticals announced that the European Medicine Agency (EMA) has...
Pearce IP’s Naomi Pearce Finalist for IP Partner of the Year – 2023 Australian Law Awards
We are proud to announce that Naomi Pearce, (Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, is a finalist for the award of Intellectual Property...
Trade Marked Goods Not ‘A Moveable Target’ in a Patent Claim
Australian and New Zealand patent examiners typically frown upon the use of trade marks in claims. Primarily, a trade mark is a sign that denotes origin, and a trade mark-branded...
BioBlast w/e 07 Jul 23
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its biosimilar to Janssen’s Stelara® (ustekinumab) Aurobindo...
Good news for inventors of computer technologies – Perram J redefines manner of manufacture following Aristocrat
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP and its Leaders Ranked in IAM Patent 1000 2023 for Litigation and Prosecution
We are delighted to announce that Pearce IP, together with three of its leaders have been ranked in IAM Patent 1000 in 2023. IAM Patent 1000 “shines a spotlight on the firms and...
The $325M Question | Commonwealth Disappointed in Landmark Appeal Court Damages Case
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 30 Jun 23
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab) Organon and Samsung Bioepis announced that Hadlima®,...
BioBlast w/e 23 Jun 23
22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel eblasakimab ASLAN Pharmaceuticals announced that it entered an...
BREAKING NEWS: COMMONWEALTH SANOFI DAMAGES DECISION DELIVERED BY FULL COURT: Sanofi avoids damages payment to the Commonwealth in Clopidogrel decision
The Full Federal Court handed down its decision this morning in the longstanding dispute as to whether the Commonwealth can claim under the “undertaking as to damages” a patentee...
Cannabidiol PBS listing expanded: Chiesi secures second PBS reimbursed indication for Epidyolex®
The PBS listing for Chiesi’s Epidyolex®, an oral cannabidiol, was expanded on 1 June 2023 to include treatment of seizures in patients with Lennoz-Gastatut Syndrome (LGS)....
‘Selection’ amendments allowable before Patent Office in failed BioNTech opposition
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast f/e 16 Jun 23
16 JUN 2023 | BR | Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to Stelara®) in Brazil BusinessWire reports that Bio-Thera Solutions...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.